[1]梁丽丽,苑　星,刘　新,等.郑州地区耐多药结核分枝杆菌gyrA和gyrB基因突变特征及对氟喹诺酮类药物耐药研究[J].新乡医学院学报,2018,35(10):874-878.[doi:10.7683/xxyxyxb.2018.10.007]
　LIANG Li-li,YUAN Xin,LIU Xin,et al.Correlation between phenotypic resistance to fluoroquinolones and gyrA and gyrB gene mutations in multidrug-resistant Mycobacterium tuberculosis in Zhengzhou，China[J].Journal of Xinxiang Medical University,2018,35(10):874-878.[doi:10.7683/xxyxyxb.2018.10.007]
点击复制

郑州地区耐多药结核分枝杆菌gyrA和gyrB基因突变特征及对氟喹诺酮类药物耐药研究
分享到：

《新乡医学院学报》[ISSN:1004-7239/CN:41-1186/R]

卷:
35
期数:
2018年10
页码:
874-878
栏目:
临床研究
出版日期:
2018-10-05

文章信息/Info

Title:
Correlation between phenotypic resistance to fluoroquinolones and gyrA and gyrB gene mutations in multidrug-resistant Mycobacterium tuberculosis in Zhengzhou，China
作者:
梁丽丽1; 苑　星1; 刘　新1; 崔秀琴2; 高　谦3
（1.河南省胸科医院内六科，河南　郑州　450000；2.新乡医学院第一附属医院结核内二科，河南　卫辉　453100；3.复旦大学上海医学院教育部分子病毒学重点实验室，上海　200032）
Author(s):
LIANG Li-li1; YUAN Xin1; LIU Xin1; CUI Xiu-qin2; GAO Qian3
（1.Department of Internal Medicine，Henan Provincial Chest Hospital，Zhengzhou 450000，Henan Province，China；2.The Second Department of Tuberculosis,the First Affiliated Hospital of Xinxiang Medical University，Weihui 453100，Henan Province，China；　3.Key Laboratory of Medical Molecular Virology，Institutes of Biomedical Sciences and Institute of Medical Microbiology，Shanghai Medical College of Fudan University，Shanghai 200030，China）
关键词:
结核分枝杆菌; 氟喹诺酮类; 氧氟沙星; 莫西沙星; 基因型; 耐多药; 突变; gyrA基因; gyrB基因
Keywords:
Mycobacterium tuberculosis; fluroquinolones; ofloxacin; moxifloxacin; genotype; multidrug resistance; mutation; gyrA gene; gyrBgene
分类号:
R378.91+1
DOI:
10.7683/xxyxyxb.2018.10.007
文献标志码:
A
摘要:
目的　分析郑州地区耐多药（MDR）结核分枝杆菌（MTB）临床分离株中gyrA和gyrB基因突变特征及其对氟喹诺酮类（FQs）药物耐药的特点。方法　收集2015年5月至2016年12月河南省胸科医院收治的256例肺结核患者的痰标本，进行MTB固体罗氏培养、液体分枝杆菌培养，MTB培养阳性者行比例法药物敏感性试验，采用聚合酶链式反应扩增MDR MTB的gyrA和gyrB基因，对扩增产物进行测序和序列比对分析。应用耐药基因判断MDR MTB对FQs药物耐药的敏感性和特异性。结果　256例患者中MTB培养阳性215例，其中非MDR肺结核患者137例，MDR肺结核患者78例。78株MDR MTB临床分离株对氧氟沙星（Ofx）、0.5 mg·L-1莫西沙星（Mfx 0.5）及2.0 mg·L-1 莫西沙星（Mfx 2.0）的耐药率分别为55.1%（43/78）、55.1%（43/78）、32.1%（25/78）；137株非MDR MTB临床分离株对Ofx、Mfx 0.5及Mfx 2.0的耐药率分别为7.3%（10/137）、5.8%（8/137）、0.7%（1/137）；非MDR MTB临床分离株对Ofx、Mfx0.5、Mfx2.0 的耐药率显著低于MDR MTB临床分离株（χ2=61.21、66.73、45.87，P<0.001）。gyrA基因、gyrB基因在Ofx耐药株中的突变率分别为90.7%(39/43)、11.6%(5/45)；gyrA基因、gyrB基因在Mfx 0.5耐药株中的突变率分别为88.4%（38/43）、11.6%（5/43）；gyrA基因、gyrB基因在Mfx 2.0耐药株中的突变率分别为100.0%（25/25）、12.0%（3/25）。以FQs药物敏感性试验结果为金标准，gyrA基因突变判断MDR MTB对Ofx、Mfx 0.5、Mfx 2.0耐药的敏感性分别为90.7%、88.4%、58.1%，特异性分别为88.6%、85.7%、100.0%，gyrB基因突变判断MDR MTB对Ofx、Mfx 0.5、Mfx 2.0耐药的敏感性分别为62.5%、62.5%、37.5%，特异性分别为45.7%、45.7%、68.6%，检测gyrA基因突变判断MDR MTB对FQs药物耐药的特异性高于gyrB基因突变（χ2=17.86、15.44、13.92，P<0.001），检测gyrA基因突变判断MDR MTB对Ofx耐药的敏感性高于gyrB基因突变（χ2=4.53，P<0.05）。结论　郑州地区MDR MTB对FQs耐药率较高，耐药的主要原因是gyrA基因突变，最常见的gyrA基因突变位于94位点。
Abstract:
Objective　To analyze the characteristics of gyrA and gyrB gene mutations and the phenotypic resistance to fluoroquinolones（FQs） in multi-drug resistant（MDR） Mycobacterium tuberculosis（MTB） isolates in Zhengzhou，China.Methods　The sputum samples of 256 patients with pulmonary tuberculosis were collected in Henan Provincial Chest Hospital from May 2015 to December 2016.The sputum samples were performed with MTB solid Roche culture method and liquid culture method.The samples with positive MTB were performed with proportional drug sensitivity test.The gyrA and gyrB genes of MDR MTB were amplified by PCR，and the amplified products were sequenced and analyzed.The sensitivity and specificity of MDR MTB to FQs were determined by Drug resistance genes.Results　In the 256 patients，MTB culture was positive in 215 patients.Among 215 MTB positive patients，137 cases were non-MDR pulmonary tuberculosis patients and 78 cases were MDR pulmonary tuberculosis patients.The resistance rates of 78 MDR MTB isolates to ofloxacin（Ofx），0.5 mg·L-1 moxifloxacin（Mfx 0.5） and 2.0 mg·L-1 moxifloxacin(Mfx 2.0) were 55.1%（43/78），55.1%（43/78） and 32.1%（25/78） respectively.The resistance rates of 137 non-MDR MTB isolates to Ofx，Mfx 0.5 and Mfx 2.0 were 7.3%（10/137），5.8%（8/137） and 0.7%（1/137） respectively.The resistance rates of non-MDR MTB isolates to Ofx，Mfx 0.5 and Mfx 2.0 were significantly lower than those of MDR MTB isolates（χ2=61.21，66.73，45.87；P<0.001）.The mutation rate of gyrA and gyrB gene was 90.7%(39/43) and 11.6%(5/45) in Ofx resistant strains.The mutation rate of gyrA gene was 88.4%（38/43） in Mfx 0.5 resistant strains，and the mutation rate of gyrB gene was 11.6%（5/43） in Mfx 0.5 resistant strains.The mutation rates of gyrA and gyrB genes were 100.0%（25/25） and 12.0%（3/25） in Mfx 2.0 resistant strains.The sensitivity and specificity of MDR-MTB to FQs were determined by the drug-resistance gene based on the results of FQs phenotypic drug sensitivity test.The sensitivity of gyrA gene mutation in estimating the resistance of MDR MTB to Ofx，Mfx 0.5 and Mfx 2.0 was 90.7%，88.4% and 58.1% respectively；and the specificity was 88.6%，85.7% and 100.0% respectively.The sensitivity of gyrB gene mutation in estimating the resistance of MDR MTB to Ofx,Mfx 0.5,Mfx 2.0 was 62.5%,62.5 and 37.5%;and the specificity was 45.7%,45.7% and 68.6%.The specificity of judging resistance of MDR MTB to FQs drug by gyrA gene mutation was better than that by gyrB gene mutation（χ2=17.86，15.44，13.92；P<0.001）.The sensitivity of judging resistance of MDR MTB to Ofx drug resistance by gyrA gene mutation was higher than that by gyrB gene mutation（χ2=4.53，P<0.05）.Conclusion　The resistance rate of MDR MTB to fluoroquinolones is high in Zhengzhou，China.The main reason of drug resistance is gyrA gene mutation，and the most common gyrA gene mutation is located at 94 site.

参考文献/References:

［1］　WORLD HEALTH ORGANIZATION.Global Tuberculosis Report 2017［M］.Geneva：World Health Organization，2017：21-61.
［2］　WORLD HEALTH ORGANIZATION.WHO treatment guidelines for drug-resistant tuberculosis（2016 update）［M］.Geneva：World Health Organization，2016：18-45.
［3］　MALIK S，WILLBY M，SIKES D，et al.New insights into fluoroquinolone resistance in Mycobacterium tuberculosis：functional genetic analysis of gyrA and gyrB mutations［J］.PLoS One，2012，7（6）：e39754.
［4］　中华人民共和国国家卫生和计划生育委员会.中华人民共和国卫生行业标准［M］.北京：人民卫生出版社，2017：1-4.
［5］　赵雁林，王黎霞，成诗明，等.结核分枝杆菌药物敏感性试验标准化操作程序及质量保证手册［M］.北京：人民卫生出版社，2013：16-45.
［6］　王志锐，谢彤.氟喹诺酮耐药与结核分枝杆菌中gyrA和gyrB基因突变的研究进展［J］.医学综述，2017，23（13）：2516-2521.
［7］　刘志广，郭倩，魏剑浩，等.结核分枝杆菌gyrA基因突变与氧氟沙星耐药水平的相关性研究［J］.实用预防医学，2015，22（6）：641-644.
［8］　DISTATTHAKIT A，PRAMMANANAN T，TRIBUDDHARAT C，et al.Role of gyrB mutations in pre-extensively and extensively drug-resistant tuberculosis in Thai clinical isolates［J］.Antimicrob Agents Chemother，2016，60（9）：5189-5197.

相似文献/References:

[1]李岩,邓军霞,管大伟.结核杆菌pIHSP65真核表达载体的构建和表达 [J].新乡医学院学报,2007,24(01):029.
[2]杨建伟,李　辉,王少华,等.间隔区寡核苷酸DNA微阵列分型在结核分枝杆菌检测中的应用[J].新乡医学院学报,2021,38(4):323.[doi:10.7683/xxyxyxb.2021.04.005]
　YANG Jianwei,LI Hui,WANG Shaohua,et al.Application of spacer oligonucleotide typing base on DNA microarray genotyping in Mycobacterium tuberculosis[J].Journal of Xinxiang Medical University,2021,38(10):323.[doi:10.7683/xxyxyxb.2021.04.005]
[3]李明瑛,姚恒波,柴青峰,等.液基细胞学涂片法检测痰抗酸杆菌对肺结核的诊断价值[J].新乡医学院学报,2019,36(4):364.[doi:10.7683/xxyxyxb.2019.04.016]
　LI Ming-ying,YAO Heng-bo,CAI Qing-feng,et al.Diagnostic value of liquid-based cytology test for sputum acid fast bacilli in pulmonary tuberculosis[J].Journal of Xinxiang Medical University,2019,36(10):364.[doi:10.7683/xxyxyxb.2019.04.016]
[4]崔俊伟,蔡瑞艳,王永亮.分子线性探针杂交法在结核分枝杆菌耐药性快速检测中的应用价值[J].新乡医学院学报,2017,34(10):920.[doi:10.7683/xxyxyxb.2017.10.014]
　CUI Jun-wei,CAI Rui-yan,WANG Yong-liang.Application value of molecular linear probe hybridization in rapid detection of drug resistance of Mycobacterium tuberculosis[J].Journal of Xinxiang Medical University,2017,34(10):920.[doi:10.7683/xxyxyxb.2017.10.014]
[5]胡潮兴,梁秋冬.基因诊断技术在脊柱结核诊断中的应用现状[J].新乡医学院学报,2023,40(1):093.[doi:10.7683/xxyxyxb.2023.01.017]
　HU Chaoxing,LIANG Qiudong.Current situation of gene diagnosis technology in the diagnosis of spinal tuberculosis[J].Journal of Xinxiang Medical University,2023,40(10):093.[doi:10.7683/xxyxyxb.2023.01.017]

更新日期/Last Update: 2018-10-05